AstraZeneca Pharma India Appoints Vinay Sharma as Business Unit Head for Rare Disease
Published On : 2024-03-25T14:07:05+0530 [ IST ] |
Author : Mayur_Tembhare
Reading Time : 2 mins
Home
Business
India :
AstraZeneca Pharma India Ltd. has announced a significant appointment, welcoming Vinay Sharma as the new Business Unit Head for Rare Disease, effective July 1, 2024. This strategic move underscores the company's commitment to advancing its presence and expertise in the field of rare diseases.
Vinay Sharma, currently serving as the Business Unit Head for Respiratory and Immunology in the Philippines, brings with him a wealth of experience and expertise garnered over a distinguished career spanning more than two decades. Armed with a post-graduate degree in marketing management and business administration, Sharma's industry acumen and leadership prowess are poised to drive the company's rare disease portfolio to new heights.
Having joined AstraZeneca India in 2013 as the Marketing Manager for Diabetes, Sharma has traversed a remarkable journey within the organization, ascending to various leadership roles in sales, marketing, and patient advocacy across both domestic and international markets. His multifaceted contributions have been instrumental in shaping the company's strategic initiatives and market penetration efforts.
Of notable mention is Sharma's pivotal role in spearheading the successful launch of Forxiga, a groundbreaking pharmaceutical innovation, in the Indian market. His adept leadership and strategic vision have consistently propelled the company towards achieving its objectives and expanding its footprint in the healthcare landscape.
The appointment of Vinay Sharma comes at a crucial juncture for AstraZeneca Pharma India, as it endeavors to reinforce its commitment to addressing the unmet needs of patients grappling with rare diseases. With Sharma at the helm, the company is poised to embark on a transformative journey, leveraging his expertise and insights to drive innovation, foster strategic partnerships, and deliver impactful solutions to patients in need.
On the stock exchange front, AstraZeneca Pharma India shares witnessed a positive uptick, closing higher by 1.37 per cent on the NSE at ₹5,100 in Friday's trading session. This favorable market response underscores investor confidence in the company's strategic direction and leadership appointments, auguring well for its future growth trajectory.
Source : Business Line
Tags : Forxiga , Rare Disease , Vinay Sharma , AstraZeneca Pharma India , industry experience , appointment , Leadership ,
Summary : AstraZeneca Pharma India Ltd. has announced the appointment of Vinay Sharma as the Business Unit Head for Rare Disease, effective July 1, 2024. Sharma, currently serving as the head of Respiratory and Immunology in the Philippines, brings over 23 years of industry experience to his new role. He holds a post-graduate degree in marketing management and business administration and has held various leadership positions in sales, marketing, and patient advocacy across AstraZeneca India and other international markets. Sharma played a pivotal role in launching Forxiga in India.
